MAXHEALTH1,033.10

Max Healthcare Institute Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPFORTISMEDANTADRREDDYCIPLASUNPHARMADIVISLABTORNTPHARMMcap ₹1.01L Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
MAXHEALTH
FY26
APOLLOHOSP
FY26
FORTIS
FY26
MEDANTA
FY26
Peer
Median
Valuation — at last close
P/E69.66×65.86×65.36×70.35×65.86× +6%
P/B9.36×12.82×6.70×9.83×9.83× -5%
EV/EBITDA46.08×34.95×33.84×43.75×34.95× +32%
Market Cap₹1.01L Cr₹1.28L Cr₹68,097 Cr₹39,148 Cr₹68,097 Cr +48%
Growth
Revenue CAGR 3Y22.43%14.94%13.17%17.85%14.94% +50%
Revenue CAGR 5Y27.30%19.03%17.76%18.40% +48%
Net Income CAGR 3Y9.34%33.35%18.91%19.33%19.33% -52%
Revenue YoY (latest Q)16.70%20.56%17.46%26.50%20.56% -19%
Net Income YoY (latest Q)4.87%38.41%2.26%-1.09%2.26% +115%
Profitability
EBITDA Margin26.79%14.94%22.84%20.84%20.84% +29%
Net Income Margin17.23%7.94%11.66%12.56%11.66% +48%
Return on Common Equity13.42%19.47%10.25%13.97%13.97% -4%
Return on Capital Employed11.94%18.41%11.81%13.20%13.20% -10%
Return on Assets8.37%9.02%6.67%9.38%9.02% -7%
Credit & Quality
Total Debt/Equity0.32×0.57×0.28×0.30×0.30× +7%
Interest Coverage7.64×6.44×5.20×8.80×6.44× +19%
Scale — latest FY
Revenue / Total Income₹8,373 Cr₹25,229 Cr₹9,128 Cr₹4,410 Cr₹9,128 Cr -8%
Net Income₹1,442 Cr₹2,003 Cr₹1,064 Cr₹554 Cr₹1,064 Cr +36%
Total Assets₹17,231 Cr₹22,197 Cr₹15,966 Cr₹5,905 Cr₹15,966 Cr +8%
EPS₹14.83₹135.04₹13.8₹20.71₹20.71 -28%
Book Value per Share₹110.43₹693.64₹134.69₹148.29₹148.29 -26%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 146%.